证券日报网讯2月26日，力生制药（002393）在互动平台回答投资者提问时表示，力生制药为深交所上 市企业，属医药制造及生物医药行业，是国家高新技术企业、国家企业技术中心、国家级绿色工厂， 2022年入选国务院国资委"科改示范企业"。公司成立于1951年，主营药品研发、生产与销售，产品覆盖 心脑血管、消化、抗感染等15大类共296个品种，拥有专利授权111项、注册商标189个。公司在缓控释 制剂领域布局较早，核心技术包括以激光打孔为基础的渗透泵缓控释技术。相关技术已应用于甲磺酸多 沙唑嗪缓释片等产品，可实现药物长效平稳释放。公司围绕渗透泵制剂相关设备拥有自主专利，生产装 备具备较高自动化水平与生产效率。目前公司已初步建成缓控释制剂平台，为天津市缓控释及固体分散 体药物制剂重点实验室，同时拥有骨架缓释、缓释微丸、固体分散体等多项制剂技术，形成了较为完整 的制剂技术体系，在高端制剂领域实现了关键装备与辅料的国产化突破，是国内少数具备渗透泵缓控释 制剂产业化能力的企业之一。 ...

仟源医药（300254）(300254.SZ)公告，公司董事会授权经营层以自有资金与舟山荣豪贸易有限公司(简 称"舟山荣豪")联合参与海力生集团有限公司所持有浙江仟源海力生制药（002393）有限公司(简称"仟源 海力生")40%股权司法拍卖，公司与舟山荣豪各竞拍20%仟源海力生股权。于2026年2月25日，根据浙江 省宁波市鄞州区人民法院淘宝网司法拍卖网络平台的公告信息，公司与舟山荣豪联合以1.55亿元价格竞 得仟源海力生40%股权，公司持有仟源海力生股权将增加至80%。 ...

Core Viewpoint - The report highlights the growth in the chemical raw materials and products manufacturing industry in China, indicating a positive trend in the number of enterprises and overall market potential from 2026 to 2032 [1] Industry Summary - As of January to December 2025, the number of enterprises in the chemical raw materials and products manufacturing industry reached 27,102, an increase of 815 compared to the previous year, representing a year-on-year growth of 3.1% [1] - This sector accounts for 5.15% of the total industrial enterprises in China, reflecting its significance within the broader industrial landscape [1] - The report is based on data from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - The report mentions several listed companies in the chemical sector, including Hainan Haiyao (000566), Northeast Pharmaceutical (000597), and others, indicating a diverse range of players in the market [1] - Zhiyan Consulting provides comprehensive industry research reports, business plans, feasibility studies, and customized services, emphasizing its role in supporting investment decisions in the chemical industry [1]

新股动态： ①通领科技(920187)今日申购，发行价29.62元。 ② 易思维(688816)今日上市，发行价55.95 元。 行业大事： ①国新办举行新闻发布会，介绍2026"乐购新春"春节特别活动、保障春节市场供应有 关情况。 ②上海市政府举行新闻发布会，介绍《上海市国民经济和社会发展第十五个五年规划纲要》 有关内容。 ③海南全省首批在海口、三亚、儋州三个地级市共开设5家日用消费品 免税店，各店定于今 日南方小年开业。 ④ 中芯国际举行2025年第四季度业绩说明会。 ⑤欧佩克公布月度原油市场报告。 ⑥ 王毅将访问匈牙利并赴德国出席第62届慕尼黑安全会议。 ⑦World Defense Show2026第三届沙特(利雅 得)国际防务展今日至2月12日举行。 ⑧央行、国家发改委等八部门联合发布通知，重申加强虚拟货币 交易炒作风险监测、预警和处置。 经济数据公布： ①中国1月CPI同比，前值0.8。 ②中国1月PPI同比， 前值-1.9。 ③美国1月失业率，预期4.4，前值4.4。 ④美国1月非农就业人口变动(万人)，预期6.8，前值 5。 ⑤今日有750亿元7天期逆回购到期。 A股动态： ①6家上市公司迎来 ...

新股动态： 今日共有3只新股上市，分别为 林平发展（发行价37.88元）、 电科蓝天（发行价9.47 元）、爱得科技（发行价7.67元）。此外，港股乐欣户外、爱芯元智今日上市。 行业大事： ①财政 部、海关总署、税务总局联合印发《关于河套深港科技创新合作区深圳园区货物进出口有关税收政策的 通知》，自2月10日起实施。 ②《上海市食品经营许可审查实施细则》于2月10日正式施行。 ③中共中 央政治局委员、外交部长王毅将于2月10日在广州出席2026年亚太经合组织（APEC）第一次高官会开 幕式并致辞。 ④市场监管总局、 交通运输部等四部门联合发布《重点液态食品道路散装运输联单管理 工作规范》，对植物油、酒类等五类液态食品道路散装运输实施许可管理，自7月1日起执行。 ⑤沪深 北三大交易所推出优化再融资一揽子措施，精准支持科技创新。 经济数据公布： ①美国12月零售销售 环比，预期0.4，前值0.6。 A股动态： ①9家上市公司迎来股票解禁。其中 物产金轮解禁3107.08万股， 占总股本13.97%；其他公司解禁规模较小，如 康尼机电636.88万股(0.74%)、 希荻微172.08万股(0.42%) 等，解禁占 ...

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the market entry of its raw material drug, Adenosine Phosphate, which is expected to enhance its market competitiveness and create synergy with its formulation products [1]. Group 1: Product Approval - Lifesun Pharmaceutical announced the receipt of the approval notice for the market entry of Adenosine Phosphate raw material drug [1]. - Adenosine Phosphate, previously known as Vitamin B4, is a crucial component for nucleic acids and coenzymes, participating in the synthesis of DNA and RNA [1]. - The drug is clinically used to prevent and treat leukopenia caused by various reasons, including acute granulocytopenia, particularly due to chemotherapy, radiation therapy, and benzene poisoning [1]. Group 2: Market Impact - The approval of Adenosine Phosphate is expected to facilitate industrial synergy with the company's formulation products [1]. - This development is anticipated to enhance the company's market competitiveness [1].

Overview - Tianjin Lifeng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the listing application of Adenine Phosphate raw material [2] Product Information - The product, Adenine Phosphate, is a chemical raw material with a molecular weight of 233.12 and a molecular formula of C5H5N5·H3PO4 [2] - It is used clinically to prevent and treat leukopenia caused by various reasons, particularly in cases related to chemotherapy, radiation therapy, and benzene poisoning [2] Impact on the Company - The approval of this product's listing application is expected to enhance the company's market competitiveness by creating industrial synergy with its formulation products [3]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), has received approval from the National Medical Products Administration for the marketing application of Adenosine Phosphate raw material, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - Lifesun Pharmaceutical has been granted a marketing approval notice for Adenosine Phosphate raw material [1] - Adenosine Phosphate, previously known as Vitamin B4, is essential for the synthesis of DNA and RNA, playing a crucial role in maintaining metabolic functions in living organisms [1] - The clinical applications of Adenosine Phosphate include the prevention and treatment of leukopenia caused by various factors, particularly in patients undergoing chemotherapy and radiation therapy, as well as those affected by benzene poisoning [1]

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of adenine phosphate raw material, which is expected to enhance its market competitiveness and create synergy with its formulation products [1] Group 1: Company Announcement - Lifesun Pharmaceutical announced the receipt of the approval notice for the listing application of adenine phosphate raw material from the National Medical Products Administration [1] - Adenine phosphate is a component of nucleic acids and coenzymes, involved in the synthesis of DNA and RNA in the body, and is clinically used to prevent and treat leukopenia caused by various reasons [1] Group 2: Market Implications - The approval of adenine phosphate raw material is expected to facilitate industrial synergy with the company's formulation products, thereby enhancing market competitiveness [1]